Immunity to TB and targets for immunotherapy

Immunotherapy

Volumn 4, Issue 2, 2012, Pages 187-199

  Gonzalez Juarrero, Mercedes ^a  

^a Department of Environmental and Radiological Health Sciences   (United States)

Author keywords

host targeted interventions; immunopathology; immunotherapy; TB

Indexed keywords

BCG VACCINE; CC 3052; DZHERELO; ETANERCEPT; GAMMA INTERFERON; IMMUNOMODULATING AGENT; INFLIXIMAB; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 2; INTERLEUKIN 4; MYCOBACTERIUM ANTIGEN; MYCOBACTERIUM VACCINE; PREDNISOLONE; RESIQUIMOD; SRL 172; THALIDOMIDE DERIVATIVE; TRANSCRIPTION FACTOR FOXP3; TRANSFORMING GROWTH FACTOR BETA1; TUBERCULOSTATIC AGENT; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ADAPTIVE IMMUNITY; ANTINEOPLASTIC ACTIVITY; ANTIVIRAL ACTIVITY; BACTERIAL CLEARANCE; BACTERIAL GROWTH; BACTERIAL IMMUNITY; BACTERIAL SURVIVAL; BACTERICIDAL ACTIVITY; CELL ACTIVATION; CELL PROLIFERATION; CYTOKINE PRODUCTION; DRUG SAFETY; DRUG TREATMENT FAILURE; HISTOPATHOLOGY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE STATUS; IMMUNOGENICITY; IMMUNOLOGICAL TOLERANCE; IMMUNOPATHOLOGY; IMMUNOTHERAPY; INNATE IMMUNITY; LUNG TUBERCULOSIS; MALNUTRITION; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; MULTIDRUG RESISTANT TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL; REVIEW; SHORT COURSE THERAPY; TH1 CELL; TUBERCULOSIS; TUBERCULOSIS CONTROL; UNSPECIFIED SIDE EFFECT;

ANIMALS; ANTIBODIES, BACTERIAL; ANTIGENS, BACTERIAL; ANTITUBERCULAR AGENTS; COMBINED MODALITY THERAPY; DRUG RESISTANCE, BACTERIAL; HUMANS; IMMUNOTHERAPY; MYCOBACTERIUM TUBERCULOSIS; TH1 CELLS; TUBERCULOSIS, PULMONARY; VIRULENCE;

EID: 84857540259     PISSN: 1750743X     EISSN: 17507448     Source Type: Journal    
DOI: 10.2217/imt.11.168     Document Type: Review

References (124)

1. Palanisamy GS, Smith EE, Shanley CA, Ordway DJ, Orme IM, Basaraba RJ. Disseminated disease severity as a measure of virulence of Mycobacterium tuberculosis in the guinea pig model. Tuberculosis (Edinb.) 88(4), 295-306 (2008).
2. Gupta KB, Gupta R, Atreja A, Verma M, Vishvkarma S. Tuberculosis and nutrition. Lung India 26(1), 9-16 (2009).
3. Madebo T, Lindtjorn B, Aukrust P, Berge RK. Circulating antioxidants and lipid peroxidation products in untreated tuberculosis patients in Ethiopia. Am. J. Clin. Nutr. 78(1), 117-122 (2003).
4. Chandra RK. Nutrient supplementation as adjunct therapy in pulmonary tuberculosis. Int. J. Vitam. Nutr. Res. 74(2), 144-146 (2004).
5. Armijos RX, Weigel MM, Chacon R, Flores L, Campos A. Adjunctive micronutrient supplementation for pulmonary tuberculosis. Salud Publica. Mex. 52(3), 185-189 (2010).
6. Martineau AR, Wilkinson RJ, Wilkinson KA et al. A single dose of vitamin D enhances immunity to mycobacteria. Am. J. Respir. Crit. Care Med. 176(2), 208-213 (2007).
7. Schon T, Idh J, Westman A et al. Effects of a food supplement rich in arginine in patients with smear positive pulmonary tuberculosis - a randomised trial. Tuberculosis (Edinb.) 91(5), 370-377 (2011).
8. Schon T, Elias D, Moges F et al. Arginine as an adjuvant to chemotherapy improves clinical outcome in active tuberculosis. Eur. Respir. J. 21(3), 483-488 (2003).
9. Arjanova OV, Prihoda ND, Yurchenko LV et al. Enhancement of efficacy of tuberculosis drugs with immunoxel (Dzherelo) in HIV-infected patients with active pulmonary tuberculosis. Immunotherapy 1(4), 549-556 (2009).
10. Bodnar PM, Mykhal'chyshyn HP, Reznichenko VM, Moshchych OP, Pylypchuk VS. Phytoconcentrates "dzherelo" and "lizorm" in therapy of autoimmune thyroiditis. Lik. Sprava. (8), 127-129 (2002).
11. 4+ T-cells and HIV RNA resulting from combination of anti-TB therapy with Dzherelo in TB/HIV dually infected patients. Drug Des. Dev. Ther. 2, 87-93 (2009).
12. Nikolaeva LG, Maystat TV, Pylypchuk VS, Volyanskii YL, Frolov VM, Kutsyna GA. Cytokine profiles of HIV patients with pulmonary tuberculosis resulting from adjunct immunotherapy with herbal phytoconcentrates Dzherelo and Anemin. Cytokine 44(3), 392-396 (2008).
13. Abba K, Sudarsanam TD, Grobler L, Volmink J. Nutritional supplements for people being treated for active tuberculosis. Cochrane Database Syst. Rev. 4, CD006086 (2008).
14. Kennedy N, Ramsay A, Uiso L, Gutmann J, Ngowi FI, Gillespie SH. Nutritional status and weight gain in patients with pulmonary tuberculosis in Tanzania. Trans. R. Soc. Trop. Med. Hyg. 90(2), 162-166 (1996).
15. Sturgill-Koszycki S, Schlesinger PH, Chakraborty P et al. Lack of acidification in Mycobacterium phagosomes produced by exclusion of the vesicular proton-ATPase. Science 263(5147), 678-681 (1994).
16. Orme IM, Cooper AM. Cytokine/chemokine cascades in immunity to tuberculosis. Immunol. Today 20(7), 307-312 (1999).
17. Voskuil MI, Schnappinger D, Visconti KC et al. Inhibition of respiration by nitric oxide induces a Mycobacterium tuberculosis dormancy program. J. Exp. Med. 198(5), 705-713 (2003).
18. Voskuil MI, Visconti KC, Schoolnik GK. Mycobacterium tuberculosis gene expression during adaptation to stationary phase and low-oxygen dormancy. Tuberculosis (Edinb.) 84(3-4), 218-227 (2004).
19. Gonzalez-Juarrero M, Turner OC, Turner J, Marietta P, Brooks JV, Orme IM. Temporal and spatial arrangement of lymphocytes within lung granulomas induced by aerosol infection with Mycobacterium tuberculosis. Infect. Immun. 69(3), 1722-1728 (2001).
20. Ulrichs T, Kosmiadi GA, Trusov V et al. Human tuberculous granulomas induce peripheral lymphoid follicle-like structures to orchestrate local host defence in the lung. J. Pathol. 204(2), 217-228 (2004).
21. Ordway D, Henao-Tamayo M, Orme IM, Gonzalez-Juarrero M. Foamy macrophages within lung granulomas of mice infected with Mycobacterium tuberculosis express molecules characteristic of dendritic cells and antiapoptotic markers of the TNF receptor-associated factor family. J. Immunol. 175(6), 3873-3881 (2005).
22. Glatman-Freedman A. Advances in antibody-mediated immunity against Mycobacterium tuberculosis: Implications for a novel vaccine strategy. FEMS Immunol. Med. Microbiol. 39(1), 9-16 (2003).
23. Peresi E, Silva SM, Calvi SA, Marcondes- Machado J. Cytokines and acute phase serum proteins as markers of inflammatory regression during the treatment of pulmonary tuberculosis. J. Bras. Pneumol. 34(11), 942-949 (2008).
24. Eum SY, Lee YJ, Min JH et al. Association of antigen-stimulated release of tumor necrosis factor?a in whole blood with response to chemotherapy in patients with pulmonary multidrug-resistant tuberculosis. Respiration 80(4), 275-284 (2010).
25. Ameglio F, Casarini M, Capoluongo E, Mattia P, Puglisi G, Giosue S. Post-treatment changes of six cytokines in active pulmonary tuberculosis: differences between patients with stable or increased fibrosis. Int. J. Tuberc. Lung Dis. 9(1), 98-104 (2005).
26. Ordway DJ, Shang S, Henao-Tamayo M et al. BCG mediated protection against W-Beijing strains of Mycobacterium tuberculosis is diminished concomitant with the emergence of regulatory T cells. Clin. Vacc. Immunol. 18(9), 1527-1535 (2011).
27. Shang S, Harton M, Tamayo MH et al. Increased FoxP3 expression in guinea pigs infected with W-Beijing strains of M. Tuberculosis. Tuberculosis (Edinb.) 91(5), 378-385 (2011).
28. Keane J. TNF-blocking agents and tuberculosis: new drugs illuminate an old topic. Rheumatology (Oxf.) 44(6), 714-720 (2005).
29. Ordway D, Higgins DM, Sanchez-Campillo J et al. XCL1 (lymphotactin) chemokine produced by activated CD8 T cells during the chronic stage of infection with Mycobacterium tuberculosis negatively affects production of IFNσg by CD4 T cells and participates in granuloma stability. J. Leukoc. Biol. 82(5), 1221-1229 (2007).
30. Prideaux B, Dartois VR, Staab D et al. High-sensitivity MALDI?MRM?MS imaging of moxifloxacin distribution in tuberculosis-infected rabbit lungs and granulomatous lesions. Analyt. Chem. 83(6), 2112-2118 (2011).
31. Wallis RS, Kyambadde P, Johnson JL et al. A study of the safety, immunology, virology, and microbiology of adjunctive etanercept in HIV?1-associated tuberculosis. AIDS 18(2), 257-264 (2004).
32. Brock DT. Robert Koch: A Life in Medicine and Bacteriology. American Society for Microbiology Press, Washington, DC, USA, 20005-24171 (1999).
33. Cardona PJ. RUTI: A new chance to shorten the treatment of latent tuberculosis infection. Tuberculosis (Edinb.) 86(3-4), 273-289 (2006).
34. Vilaplana C, Montane E, Pinto S et al. Double-blind, randomized, placebo-controlled Phase 1 clinical trial of the therapeutical antituberculous vaccine RUTI. Vaccine 28(4), 1106-1116 (2010).
35. Vilaplana C, Gil O, Caceres N, Pinto S, Diaz J, Cardona PJ. Prophylactic effect of a therapeutic vaccine against TB based on fragments of Mycobacterium tuberculosis. PLoS ONE 6(5), E20404 (2011).
36. Corlan E, Marica C, Macavei C, Stanford JL, Stanford CA. Immunotherapy with Mycobacterium vaccae in the treatment of tuberculosis in Romania. 2. Chronic or relapsed disease. Respir. Med. 91(1), 21-29 (1997).
37. Dlugovitzky D, Bottasso O, Dominino JC et al. Clinical and serological studies of tuberculosis patients in Argentina receiving immunotherapy with Mycobacterium vaccae (SRL 172). Respir. Med. 93(8), 557-562 (1999).
38. Dlugovitzky D, Stanford C, Stanford J. Immunological basis for the introduction of immunotherapy with Mycobacterium vaccae into the routine treatment of TB. Immunotherapy 3(4), 557-568 (2011).
39. Johnson JL, Kamya RM, Okwera A et al. Randomized controlled trial of Mycobacterium vaccae immunotherapy in non-human immunodeficiency virus-infected Ugandan adults with newly diagnosed pulmonary tuberculosis. The Uganda-Case Western Reserve University Research Collaboration. J. Infect. Dis. 181(4), 1304-1312 (2000).
40. Johnson JL, Nunn AJ, Fourie PB et al. Effect of Mycobacterium vaccae (SRL172) immunotherapy on radiographic healing in tuberculosis. Int. J. Tuberc. Lung Dis. 8(11), 1348-1354 (2004).
41. Lahey T, Arbeit RD, Bakari M et al. Immunogenicity of a protective whole cell mycobacterial vaccine in HIV-infected adults: A Phase 3 study in Tanzania. Vaccine 28(48), 7652-7658 (2010).
42. Onyebujoh PC, Abdulmumini T, Robinson S, Rook GA, Stanford JL. Immunotherapy with Mycobacterium vaccae as an addition to chemotherapy for the treatment of pulmonary tuberculosis under difficult conditions in Africa. Respir. Med. 89(3), 199-207 (1995).
43. Stanford J, Stanford C, Grange J. Immunotherapy with Mycobacterium vaccae in the treatment of tuberculosis. Front. Biosci. 9, 1701-1719 (2004).
44. Vuola JM, Ristola MA, Cole B et al. Immunogenicity of an inactivated mycobacterial vaccine for the prevention of HIV-associated tuberculosis: A randomized, controlled trial. AIDS 17(16), 2351-2355 (2003).
45. Wang W, Jin G, Ye Y et al. A clinical study on vaccine of Mycobacterium vaccae in treating pulmonary tuberculosis. Zhonghua Jie He He Hu Xi Za Zhi 22(2), 108-110 (1999).
46. Waddell RD, Chintu C, Lein AD et al. Safety and immunogenicity of a five-dose series of inactivated Mycobacterium vaccae vaccination for the prevention of HIV-associated tuberculosis. Clin. Infect. Dis. 30(Suppl. 3), S309-S315 (2000).
47. Von Reyn CF, Mtei L, Arbeit RD et al. Prevention of tuberculosis in bacille calmette-guerin-primed, HIV-infected adults boosted with an inactivated whole-cell mycobacterial vaccine. AIDS 24(5), 675-685 (2010).
48. Baroux N, D'Ortenzio E. Tuberculosis in reunion island: Epidemiological characteristics of notified cases, 2000-2007. Med. Mal. Infect. 40(1), 12-17 (2010).
49. Mwinga A, Nunn A, Ngwira B et al. Mycobacterium vaccae (SRL172) immunotherapy as an adjunct to standard antituberculosis treatment in HIV-infected adults with pulmonary tuberculosis: A randomised placebo-controlled trial. Lancet 360(9339), 1050-1055 (2002).
50. Orme IM. Development of new vaccines and drugs for TB: limitations and potential strategic errors. Future Microbiol. 6(2), 161-177 (2011).
51. Rook GAW, Lowrie DB, Hernndez-Pando R. Immunotherapeutics for tuberculosis in experimental animals: Is there a common pathway activated by effective protocols? J. Infect. Dis. 196(2), 191-198 (2007).
52. Holland SM. Cytokine therapy of mycobacterial infections. Adv. Intern. Med. 45, 431-452 (2000).
53. Tomioka H. Adjunctive immunotherapy of mycobacterial infections. Curr. Pharm. Des. 10(26), 3297-3312 (2004).
54. Toossi Z. Adjunctive immunotherapy of tuberculosis. Cytokines Cell Mol. Ther. 4(2), 105-112 (1998).
55. Tsuyuguchi I. Immunotherapy for MDR?TB (multi-drug resistant tuberculosis) - its feasibility. Kekkaku 74(6), 479-491 (1999).
56. Churchyard GJ, Kaplan G, Fallows D, Wallis RS, Onyebujoh P, Rook GA. Advances in immunotherapy for tuberculosis treatment. Clin. Chest Med. 30(4), 769-782, ix (2009).
57. Ribeiro-Rodrigues R, Resende CoT, Johnson JL et al. Sputum cytokine levels in patients with pulmonary tuberculosis as early markers of mycobacterial clearance. Clin. Diagn. Lab. Immunol. 9(4), 818-823 (2002).
58. Djoba Siawaya JF, Beyers N, Van Helden P, Walzl G. Differential cytokine secretion and early treatment response in patients with pulmonary tuberculosis. Clin. Exp. Immunol. 156(1), 69-77 (2009).
59. Berktas M, Guducuoglu H, Bozkurt H, Onbasi KT, Kurtoglu MG, Andic S. Change in serum concentrations of interleukin-2 and interferonγg during treatment of tuberculosis. J. Int. Med. Res. 32(3), 324-330 (2004).
60. Johnson B, Bekker LG, Ress S, Kaplan G. Recombinant interleukin 2 adjunctive therapy in multidrug-resistant tuberculosis. Novartis Found. Symp. 217, 99-106 (1998).
61. Johnson BJ, Estrada I, Shen Z et al. Differential gene expression in response to adjunctive recombinant human interleukin-2 immunotherapy in multidrug-resistant tuberculosis patients. Infect. Immun. 66(6), 2426-2433 (1998).
62. Johnson BJ, Ress SR, Willcox P et al. Clinical and immune responses of tuberculosis patients treated with low-dose IL- 2 and multidrug therapy. Cytokines Mol. Ther. 1(3), 185-196 (1995).
63. Johnson JL, Ssekasanvu E, Okwera A et al. Randomized trial of adjunctive interleukin-2 in adults with pulmonary tuberculosis. Am. J. Respir. Crit. Care Med. 168(2), 185-191 (2003).
64. Gao XF, Yang ZW, Li J. Adjunctive therapy with interferonγg for the treatment of pulmonary tuberculosis: A systematic review. Int. J. Infect. Dis. 15(9), E594-E600 (2011).
65. Giosue S, Casarini M, Alemanno L et al. Effects of aerosolized interferon?a in patients with pulmonary tuberculosis. Am. J. Respir. Crit. Care Med. 158(4), 1156-1162 (1998).
66. Hirsch CS, Toossi Z, Othieno C et al. Depressed T-cell interferonγg responses in pulmonary tuberculosis: Analysis of underlying mechanisms and modulation with therapy. J. Infect. Dis. 180(6), 2069-2073 (1999).
67. Murray HW. Interferonγg and host antimicrobial defense: Current and future clinical applications. Am. J. Med. 97(5), 459-467 (1994).
68. Reljic R. IFNσg therapy of tuberculosis and related infections. J. Interferon Cytokine Res. 27(5), 353-364 (2007).
69. Schluger NW, Perez D, Liu YM. Reconstitution of immune responses to tuberculosis in patients with HIV infection who receive antiretroviral therapy. Chest 122(2), 597-602 (2002).
70. Suarez-Mendez R, Garcia-Garcia I, Fernandez-Olivera N et al. Adjuvant interferon g in patients with drug-resistant pulmonary tuberculosis: A pilot study. BMC Infect. Dis. 4, 44 (2004).
71. Greinert U, Ernst M, Schlaak M, Entzian P. Interleukin?12 as successful adjuvant in tuberculosis treatment. Eur. Respir. J. 17(5), 1049-1051 (2001).
72. Nolt D, Flynn JL. Interleukin?12 therapy reduces the number of immune cells and pathology in lungs of mice infected with Mycobacterium tuberculosis. Infect. Immun. 72(5), 2976-2988 (2004).
73. 4+ T cells in lungs of CCR7-/- mice. J. Immunol. 184(2), 895-901 (2010).
74. Gonzalez-Juarrero M, Turner J, Basaraba RJ, Belisle JT, Orme IM. Florid pulmonary inflammatory responses in mice vaccinated with antigen?85 pulsed dendritic cells and challenged by aerosol with Mycobacterium tuberculosis. Cell. Immunol. 220(1), 13-19 (2002).
75. Kaplan G, Post FA, Moreira AL et al. Mycobacterium tuberculosis growth at the cavity surface: A microenvironment with failed immunity. Infect. Immun. 71(12), 7099-7108 (2003).
76. Gonzalez-Juarrero M, Kingry LC, Ordway DJ et al. Immune response to Mycobacterium tuberculosis and identification of molecular markers of disease. Am. J. Respir. Cell Mol. Biol. 40(4), 398-409 (2009).
77. Taylor JL, Ordway DJ, Troudt J, Gonzalez?Juarrero M, Basaraba RJ, Orme IM. Factors associated with severe granulomatous pneumonia in Mycobacterium tuberculosis-infected mice vaccinated therapeutically with hsp65 DNA. Infect. Immun. 73(8), 5189-5193 (2005).
78. Kaplan G. Cytokine regulation of disease progression in leprosy and tuberculosis. Immunobiology 191(4-5), 564-568 (1994).
79. Gutierrez-Rodriguez O. Thalidomide. A promising new treatment for rheumatoid arthritis. Arthrit. Rheum. 27(10), 1118-1121 (1984).
80. Tramontana JM, Utaipat U, Molloy A et al. Thalidomide treatment reduces tumor necrosis factor a production and enhances weight gain in patients with pulmonary tuberculosis. Mol. Med. 1(4), 384-397 (1995).
81. Tsenova L, Sokol K, Freedman VH, Kaplan G. A combination of thalidomide plus antibiotics protects rabbits from mycobacterial meningitis-associated death. J. Infect. Dis. 177(6), 1563-1572 (1998).
82. Corral LG, Muller GW, Moreira AL et al. Selection of novel analogs of thalidomide with enhanced tumor necrosis factor a inhibitory activity. Mol. Med. 2(4), 506-515 (1996).
83. Koo MS, Manca C, Yang G et al. Phosphodiesterase 4 inhibition reduces innate immunity and improves isoniazid clearance of Mycobacterium tuberculosis in the lungs of infected mice. PLoS ONE 6(2), E17091 (2011).
84. Tsenova L, Mangaliso B, Muller G et al. Use of IMiD3, a thalidomide analog, as an adjunct to therapy for experimental tuberculous meningitis. Antimicrob. Agents Chemother. 46(6), 1887-1895 (2002).
85. Wallis RS. Reactivation of latent tuberculosis by TNF blockade: The role of interferon g. J. Investig. Dermatol. Symp. Proc. 12(1), 16-21 (2007).
86. Wyser C, Walzl G, Smedema JP, Swart F, van Schalkwyk EM, van De Wal BW. Corticosteroids in the treatment of tuberculous pleurisy. A double-blind, placebo-controlled, randomized study. Chest 110(2), 333-338 (1996).
87. Mayanja-Kizza H, Jones-Lopez E, Okwera A et al. Immunoadjuvant prednisolone therapy for HIV-associated tuberculosis: A Phase 2 clinical trial in Uganda. J. Infect. Dis. 191(6), 856-865 (2005).
88. Wallis RS. Reconsidering adjuvant immunotherapy for tuberculosis. Clin. Infect. Dis. 41(2), 201-208 (2005).
89. Byrne ST, Denkin SM, Zhang Y. Aspirin and ibuprofen enhance pyrazinamide treatment of murine tuberculosis. J. Antimicrob. Chemother. 59(2), 313-316 (2007).
90. Byrne ST, Denkin SM, Zhang Y. Aspirin antagonism in isoniazid treatment of tuberculosis in mice. Antimicrob. Agents Chemother. 51(2), 794-795 (2007).
91. Hirsch CS, Yoneda T, Averill L, Ellner JJ, Toossi Z. Enhancement of intracellular growth of Mycobacterium tuberculosis in human monocytes by transforming growth factorβ 1. J. Infect. Dis. 170(5), 1229-1237 (1994).
92. Othieno C, Hirsch CS, Hamilton BD, Wilkinson K, Ellner JJ, Toossi Z. Interaction of Mycobacterium tuberculosis-induced transforming growth factor b 1 and interleukin-10. Infect. Immun. 67(11), 5730-5735 (1999).
93. Ellner JJ. Immunoregulation in TB: observations and implications. Clin. Transl. Sci. 3(1), 23-28 (2010).
94. Turner J, Gonzalez-Juarrero M, Ellis DL et al. In vivo IL-10 production reactivates chronic pulmonary tuberculosis in C57BL/6 mice. J. Immunol. 169(11), 6343-6351 (2002).
95. Turner J, Gonzalez-Juarrero M, Saunders BM et al. Immunological basis for reactivation of tuberculosis in mice. Infect. Immun. 69(5), 3264-3270 (2001).
96. Ordway D, Henao-Tamayo M, Harton M et al. The hypervirulent Mycobacterium tuberculosis strain HN878 induces a potent TH1 response followed by rapid down-regulation. J. Immunol. 179(1), 522-531 (2007).
97. Hernandez-Pando R, Orozco H, Arriaga K, Sampieri A, Larriva-Sahd J, Madrid- Marina V. Analysis of the local kinetics and localization of interleukin?1a, tumour necrosis factor?a and transforming growth factor?b, during the course of experimental pulmonary tuberculosis. Immunology 90(4), 607-617 (1997).
98. Beamer GL, Flaherty DK, Assogba BD et al. Interleukin-10 promotes Mycobacterium tuberculosis disease progression in CBA/J mice. J. Immunol. 181(8), 5545-5550 (2008).
99. Hernandez-Pando R, Orozco-Esteves H, Maldonado HA et al. A combination of a transforming growth factorβ antagonist and an inhibitor of cyclooxygenase is an effective treatment for murine pulmonary tuberculosis. Clin. Exp. Immunol. 144(2), 264-272 (2006).
100. Hirsch CS, Ellner JJ, Blinkhorn R, Toossi Z. In vitro restoration of T cell responses in tuberculosis and augmentation of monocyte effector function against Mycobacterium tuberculosis by natural inhibitors of transforming growth factor b. Proc. Natl Acad. Sci. USA 94(8), 3926-3931 (1997).
101. Rosas-Taraco AG, Higgins DM, Sanchez- Campillo J, Lee EJ, Orme IM, Gonzalez-Juarrero M. Local pulmonary immunotherapy with siRNA targeting TGFb1 enhances antimicrobial capacity in Mycobacterium tuberculosis infected mice. Tuberculosis (Edinb.) 91(1), 98-106 (2011).
102. Hoff DR, Ryan GJ, Driver ER et al. Location of intra- and extracellular M. tuberculosis populations in lungs of mice and guinea pigs during disease progression and after drug treatment. PLoS ONE 6(3), E17550 (2011).
103. Gonzalez-Juarrero M, Turner OC, Turner J, Marietta P, Brooks JV, Orme IM. Temporal and spatial arrangement of lymphocytes within lung granulomas induced by aerosol infection with Mycobacterium tuberculosis. Infect. Immun. 69(3), 1722-1728 (2001).
104. Turner J, Frank AA, Brooks JV, Gonzalez-Juarrero M, Orme IM. The progression of chronic tuberculosis in the mouse does not require the participation of B lymphocytes or interleukin?4. Exp. Gerontol. 36(3), 537-545 (2001).
105. Glatman-Freedman A. The role of antibody-mediated immunity in defense against Mycobacterium tuberculosis: Advances toward a novel vaccine strategy. Tuberculosis (Edinb.) 86(3-4), 191-197 (2006).
106. Glatman-Freedman A, Casadevall A. Serum therapy for tuberculosis revisited: Reappraisal of the role of antibody-mediated immunity against Mycobacterium tuberculosis. Clin. Microbiol. Rev. 11(3), 514-532 (1998).
107. Rich AR. The Pathogenesis of Tuberculosis. CC Thomas, Springfield, IL, USA (1944).
108. Latham A. Caseating pulmonary tuberculosis treated by tuberculin (T.R.) and fresh horse serum, both administered by the mouth. Proc. R. Soc. Med. 1(Clin. Sect.), 100-104 (1908).
109. Teitelbaum R, Glatman-Freedman A, Chen B et al. A mAb recognizing a surface antigen of Mycobacterium tuberculosis enhances host survival. Proc. Natl Acad. Sci. USA 95(26), 15688-15693 (1998).
110. Glatman-Freedman A, Mednick AJ, Lendvai N, Casadevall A. Clearance and organ distribution of Mycobacterium tuberculosis lipoarabinomannan (LAM) in the presence and absence of LAM-binding immunoglobulin M. Infect. Immun. 68(1), 335-341 (2000).
111. Pethe K, Alonso S, Biet F et al. The heparin-binding haemagglutinin of M. tuberculosis is required for extrapulmonary dissemination. Nature 412(6843), 190-194 (2001).
112. Hussain R, Shiratsuchi H, Ellner JJ, Wallis RS. PPD-specific IgG1 antibody subclass upregulate tumour necrosis factor expression in PPD-stimulated monocytes: Possible link with disease pathogenesis in tuberculosis. Clin. Exp. Immunol. 119(3), 449-455 (2000).
113. Hussain R, Shiratsuchi H, Phillips M, Ellner J, Wallis RS. Opsonizing antibodies (IgG1) up-regulate monocyte proinflammatory cytokines tumour necrosis factor?a (TNF-a) and IL?6 but not anti-inflammatory cytokine IL-10 in mycobacterial antigen-stimulated monocytes-implications for pathogenesis. Clin. Exp. Immunol. 123(2), 210-218 (2001).
114. Rook GA, Onyebujoh P, Wilkins E et al. A longitudinal study of per cent agalactosyl IgG in tuberculosis patients receiving chemotherapy, with or without immunotherapy. Immunology 81(1), 149-154 (1994).
115. Sartain MJ, Slayden RA, Singh KK, Laal S, Belisle JT. Disease state differentiation and identification of tuberculosis biomarkers via native antigen array profiling. Mol. Cell Proteomics 5(11), 2102-2113 (2006).
116. Samanich K, Belisle JT, Laal S. Homogeneity of antibody responses in tuberculosis patients. Infect. Immun. 69(7), 4600-4609 (2001).
117. Kunnath-Velayudhan S, Salamon H, Wang HY et al. Dynamic antibody responses to the Mycobacterium tuberculosis proteome. Proc. Natl Acad. Sci. USA 107(33), 14703-14708 (2010).
118. Lyashchenko K, Colangeli R, Houde M, Al Jahdali H, Menzies D, Gennaro ML. Heterogeneous antibody responses in tuberculosis. Infect. Immun. 66(8), 3936-3940 (1998).
119. Rawls KA, Grundner C, Ellman JA. Design and synthesis of nonpeptidic, small molecule inhibitors for the Mycobacterium tuberculosis protein tyrosine phosphatase PtpB. Organic Biomol. Chem. 8(18), 4066-4070 (2010).
120. Ott PA, Adams S. Small-molecule protein kinase inhibitors and their effects on the immune system: Implications for cancer treatment. Immunotherapy 3(2), 213-227 (2011).
121. Lammas DA, Stober C, Harvey CJ, Kendrick N, Panchalingam S, Kumararatne DS. ATP-induced killing of mycobacteria by human macrophages is mediated by purinergic P2Z(P2X7) receptors. Immunity 7(3), 433-444 (1997).
122. Moisan J, Wojciechowski W, Guilbault C et al. Clearance of infection with Mycobacterium M. bovis BCG in mice is enhanced by treatment with S28463 (R?848), and its efficiency depends on expression of wild-type Nramp1 (resistance allele). Antimicrob. Agents Chemother. 45(11), 3059-3064 (2001).
123. Marriott JB, Westby M, Cookson S et al. CC-3052: A water-soluble analog of thalidomide and potent inhibitor of activation-induced TNF?a production. J. Immunol. 161(8), 4236-4243 (1998).
124. Wehenkel A, Bellinzoni M, Grana M et al. Mycobacterial Ser/Thr protein kinases and phosphatases: Physiological roles and therapeutic potential. Biochim. Biophys. Acta 1784(1), 193-202 (2008).